Evidence map›Paper›PMID 35930749›Full record

ArticleBlood2022

MAPK-interacting kinase 1 regulates platelet production, activation, and thrombosis.

Bhanu Kanth Manne, Robert A Campbell, Seema Bhatlekar, Abigail Ajanel, Frederik Denorme, Irina Portier, Elizabeth A Middleton, Neal D Tolley, Yasuhiro Kosaka, Emilie Montenont and 8 more

Erratum issuedOpen access · bronzeAbstract read
In one paragraph

Article in Blood, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
4.5field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 33 citations in OpenAlex.

  1. Article
  2. Platelet mTOR Is a Regulator of Sterile Immunothrombosis.Arteriosclerosis, thrombosis, and vascular biology · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors at 3 institutions in 3 countries.

Bhanu Kanth ManneUniversity of Utah Molecular Medicine Program, Salt Lake City, UT.
Robert A CampbellUniversity of Utah Molecular Medicine Program, Salt Lake City, UT.
Seema BhatlekarUniversity of Utah Molecular Medicine Program, Salt Lake City, UT.
Abigail AjanelUniversity of Utah Molecular Medicine Program, Salt Lake City, UT.ORCID 0000-0002-4601-3769
Frederik DenormeUniversity of Utah Molecular Medicine Program, Salt Lake City, UT.ORCID 0000-0003-1442-3568
Irina PortierUniversity of Utah Molecular Medicine Program, Salt Lake City, UT.
Elizabeth A MiddletonUniversity of Utah Molecular Medicine Program, Salt Lake City, UT.
Neal D TolleyUniversity of Utah Molecular Medicine Program, Salt Lake City, UT.
Yasuhiro KosakaUniversity of Utah Molecular Medicine Program, Salt Lake City, UT.
Emilie MontenontUniversity of Utah Molecular Medicine Program, Salt Lake City, UT.ORCID 0000-0001-9112-994X
Li GuoUniversity of Utah Molecular Medicine Program, Salt Lake City, UT.ORCID 0000-0003-4430-7269
Jesse W RowleyUniversity of Utah Molecular Medicine Program, Salt Lake City, UT.
Paul F BrayUniversity of Utah Molecular Medicine Program, Salt Lake City, UT.ORCID 0000-0002-8672-3183
Shancy JacobUniversity of Utah Molecular Medicine Program, Salt Lake City, UT.
Rikiro FukanagaDepartment of Biochemistry, Osaka University of Pharmaceutical Sciences, Osaka, Japan.ORCID 0000-0001-8972-8863
Christopher ProudLifelong Health, South Australian Health & Medical Research Institute, Adelaide, Australia.
Andrew S WeyrichUniversity of Utah Molecular Medicine Program, Salt Lake City, UT.
Matthew T RondinaUniversity of Utah Molecular Medicine Program, Salt Lake City, UT.
University of Utah · USOsaka University of Pharmaceutical Sciences · JPSouth Australian Health and Medical Research Institute · AU

Funding

Utah Center for Clinical and Translational ScienceUL1TR002538 · NCATS · UNIVERSITY OF UTAH · PI HESS, RACHEL, MAJERSIK, JENNIFER JUHL · 2018 to 2022
$26.0M
Translational Control of Megakaryocyte and Platelet Gene Expression in DiseaseR35HL145237 · NHLBI · UNIVERSITY OF UTAH · PI WEYRICH, ANDREW S · 2019 to 2025
$4.7M
New Therapies to Restore Vascular Integrity During SepsisR01HL130541 · NHLBI · UNIVERSITY OF UTAH · PI ODELBERG, SHANNON J, WEYRICH, ANDREW S · 2016 to 2020
$3.7M
Platelet-Mediated Neutrophil Extracellular Traps Regulate Ischemic Stroke InjuryR01HL163019 · NHLBI · WASHINGTON UNIVERSITY · PI CAMPBELL, ROBERT A · 2022 to 2025
$2.2M
Translational Control of Megakaryocyte and Platelet Function in SepsisR01HL142804 · NHLBI · UNIVERSITY OF UTAH · PI RONDINA, MATTHEW THOMAS · 2018 to 2021
$1.9M
Platelet Immune Responses in Aging and InfluenzaR01AG048022 · NIA · UNIVERSITY OF UTAH · PI RONDINA, MATTHEW THOMAS · 2014 to 2018
$1.8M
The regulation and function of platelet FcARIIA in sepsisK08HL153953 · NHLBI · UNIVERSITY OF UTAH · PI MIDDLETON, ELIZABETH ANNE · 2020 to 2024
$833k
Platelet-Leukocyte Interactions in SepsisK24HL155856 · NHLBI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI RONDINA, MATTHEW THOMAS · 2021 to 2025
$606k
Interferon-Induced Transmembrane Protein 3 (IFITM3) Regulates Thrombosis During Inflammation in AgingK01AG059892 · NIA · UNIVERSITY OF UTAH · PI CAMPBELL, ROBERT A · 2019 to 2022
$400k
CSRD VA I01 CX001696NCATS NIH HHS UL1 TR002538NHLBI NIH HHS K08 HL153953NHLBI NIH HHS K24 HL155856NHLBI NIH HHS R01 HL130541NHLBI NIH HHS R01 HL142804NHLBI NIH HHS R01 HL163019NHLBI NIH HHS R35 HL145237NIA NIH HHS K01 AG059892NIA NIH HHS R01 AG048022
6 · The paper itself

Abstract

The MAPK-interacting kinase (Mnk) family includes Mnk1 and Mnk2, which are phosphorylated and activated in response to extracellular stimuli. Mnk1 contributes to cellular responses by regulating messenger RNA (mRNA) translation, and mRNA translation influences platelet production and function. However, the role of Mnk1 in megakaryocytes and platelets has not previously been studied. The present study investigated Mnk1 in megakaryocytes and platelets using both pharmacological and genetic approaches. We demonstrate that Mnk1, but not Mnk2, is expressed and active in human and murine megakaryocytes and platelets. Stimulating human and murine megakaryocytes and platelets induced Mnk1 activation and phosphorylation of eIF4E, a downstream target of activated Mnk1 that triggers mRNA translation. Mnk1 inhibition or deletion significantly diminished protein synthesis in megakaryocytes as measured by polysome profiling and [35S]-methionine incorporation assays. Depletion of Mnk1 also reduced megakaryocyte ploidy and proplatelet forming megakaryocytes in vitro and resulted in thrombocytopenia. However, Mnk1 deletion did not affect the half-life of circulating platelets. Platelets from Mnk1 knockout mice exhibited reduced platelet aggregation, α granule secretion, and integrin αIIbβ3 activation. Ribosomal footprint sequencing indicated that Mnk1 regulates the translation of Pla2g4a mRNA (which encodes cPLA2) in megakaryocytes. Consistent with this, Mnk1 ablation reduced cPLA2 activity and thromboxane generation in platelets and megakaryocytes. In vivo, Mnk1 ablation protected against platelet-dependent thromboembolism. These results provide previously unrecognized evidence that Mnk1 regulates mRNA translation and cellular activation in platelets and megakaryocytes, endomitosis and thrombopoiesis, and thrombosis.

Indexed as

RNA, MessengerAnimalsHumansMiceRNA, Messenger

Identifiers

PMID35930749
PMCPMC9918849
OpenAlexW4289938085

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.